Introduction
Adenoviral vectors that selectively replicate in tumor cells, but have attenuated replication in normal cells have been evaluated for the treatment of certain cancers in humans. [1] [2] [3] For example, replication of a recombinant adenoviral vector can be restricted to cells that have a defect in the retinoblastoma (pRB) pathway by replacing the immediateearly E1A promoter in an adenovirus serotype 5 vector (Ad5) with the tumor-specific human E2F-1 promoter. 4, 5 Defects in the pRB pathway occur in approximately 80% of all tumors, potentially allowing the use of such oncolytic adenoviral vectors in the treatment of many different types of cancers, possibly without the potential side effects often associated with standard chemotherapy agents. However, to date, oncolytic adenoviral vectors have demonstrated only limited efficacy in the clinic, [6] [7] [8] prompting the search for methods to increase the potency of these vectors while maintaining their selectivity and safety profile.
One approach to increasing the potency of adenoviral vectors is to arm them with anticancer transgenes that may contribute to the destruction of cancer cells, adding to the tumor cell cytotoxicity that commonly results from viral replication. 9 Potential anticancer transgenes include tumor suppressor genes, for example, p53; 10 immunomodulatory genes, for example, granulocyte macrophage colony-stimulating factor (GM-CSF) 11, 12 and interleukin-24; 13 pro-drug-converting enzymes, for example, thymidine kinase 14 and cytosine deaminase 15 and proapoptotic genes, for example, tumor necrosis factor-a 16 and TRAIL. 17 Several strategies for arming the vectors and for controlling transgene expression have been used, with the most recent attempts utilizing adenoviral promoters and transcriptional control elements to regulate the expression of inserted transgenes. 15, [18] [19] [20] [21] These studies showed that linking transgene expression to adenoviral genes that are expressed late in infection, that is, after DNA replication, restricted transgene expression to tumor cells. 15, 18 This tumor-specific transgene expression improves the safety of the vector. Several insertion sites, such as the E3A region 11, 18, 22 and E3B region, 15, 18 were identified on the basis of detailed knowledge of transcription in adenoviruses. More recently, a novel transposonbased mechanism has been described that identified other potential insertion sites, even though the exact transcriptional regions had not been previously identified. 23 In the current study, various insertion sites and transcriptional control mechanisms (gene replacement, splice acceptor site) were used to regulate transgene expression in oncolytic adenoviral vectors, with the intent of determining which sites led to the highest tumorspecific transgene expression. In addition, the effect, if any, of the insertion position of the transgene in the genome on the growth and cytotoxic properties of the vectors was evaluated. Included in this comparison were vectors in which the transgene was inserted in place of the early expressing E3 gp19K region 11 and the late expressing E3 14.K region, as well as the late expressing L3 transcriptional unit. In the latter case, a bipartite splice acceptor 21 was used to link transgene expression to the L3 transcriptional unit to achieve high level of tumor-specific transgene expression. The highest levels of transgene expression were seen when the transgene was inserted into the E3 14.7K locus or after the L3 23K coding sequence. Interestingly, when the vector was used to infect nontumor targets or DNA replication was otherwise blocked, transgene expression still occurred at the E3 14.7K insertion site, but not when the L3 23K insertion site was utilized, resulting in an armed oncolytic vector that was particularly specific for expression in tumor cells only.
Materials and methods

Cells and cultured methods
All cell lines were obtained from the American Type Culture Collection (ATCC) and were maintained in fullgrowth media (FGM) DMEM High (SAFC Biosciences, Lenexa, KA, USA) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cell lines used include the lung carcinoma cell line A549 (ATCC CCL-185), the primary human diploid fibroblast cell line WI-38 (ATCC CCL-75) and the lung fibroblast cell line MRC5 (ATCC CCL-171).
Construction of oncolytic adenoviruses with GM-CSF cDNA insertions at various loci All insertions of the human GM-CSF cDNA were made using the large plasmid pAr21pAE2fF that encodes the full-length human Ad5 genome with the Ad5 packaging signal (c) after the left hand inverted terminal repeat (ITR). The Ad5 E1A promoter has been replaced by the SV40 PolyA -human E2F-1 promoter cassette as previously described. 12 All modifications were made using shuttle plasmids. In order to insert the human GM-CSF (hGM-CSF) gene into the E3 14.7K region, hGM-CSF was amplified by polymerase chain reaction (PCR) from Ad-gp19K-GM using the following primers, AACAGGAG GAGACGACTGACCATGTGGCTGCAGAGCCTGCT and TGCTTTATTATTTTTTTTTATTACTCCTGGAC TGGCTCCCAG. The PCR product was inserted into the shuttle plasmid pDr21F that contained the Ad5 genome from nucleotides 26 172-33 289, by a PCR splice overlap extension method, 24 in place of the E3 14.7 cDNA to generate the shuttle plasmid pDr21F14.7/GM. In order to insert the hGM-CSF cDNA in the L3 region downstream of Ad5 23K, a shuttle plasmid CP1524 was used containing part of the Ad5 L3 region (nucleotides 18 318-24 795). The splice acceptor sequence (SAS-TACTTATG ACTCGTACTATTGTTATTCATCCAG) was inserted at a site corresponding to Ad5 nucleotide 22 354, with the hGM-CSF cDNA inserted immediately downstream of the SAS sequence by PCR splice overlap extension in order to generate CP1588. In order to insert the hGM-CSF cDNA into the L3 region downstream of the hexon gene, the SAS-hGM-CSF cassette was inserted into CP1524 at a site corresponding to the Ad5 nucleotides 21 556 by PCR splice overlap extension to generate the shuttle plasmid CP1524-GM. Full-length clones were generated by a homologous recombination method 25, 26 by digesting the shuttle plasmid pDR21F 14.7/hGM with SpeI/FspI and co-transforming with SrfI-linearized pAr21pAE2fF into BJ5183 cells or, by digesting either CP1588 or CP524-GM with HindIII/XhoI and cotransforming into AsiI-linearized pAr21pAE2fF. The full-length clones were then digested with I-SceI and transfected into AE1 2a cells 27 to produce the oncolytic viruses Ad-23K-GM (hGM-CSF after L3 23K), AdHexon-GM (hGM-CSF) and Ad-14.7K-GM (hGM-CSF in E3 14.7K). The parental virus, OV1165 containing no hGM-CSF insertion, was produced by transfection using Lipofectamine (Life Technologies, Rockville, MD, USA) of I-SceI-digested pAr21pAE2F into AE1 2a cells. Adgp19K-GM, that contains the hGM-CSF cDNA in the E3 gp19K region, was previously described. 28 The nonreplicating E1-deleted Ad-GM-CSF was produced as previously described. 29 Large-scale production of viruses was performed on HeLa-S3 cells as previously described. 12 Virus particle titers were determined by spectrophotometry 30 and infectious viral titers were determined by plaque assay on 293HEK cells as previously described. 31 All preparations produced had a virus particle to plaque-forming unit ratio (vp:PFU) in the range of 20 to 40.
Virus yield and TCID 50 assays Assays were performed on the basis of a method previously described. 28 Briefly, A549 cells were seeded 24 h before infection. The cells were infected with virus with 50 plaque-forming units (PFU) per cell. The cells and supernatant were harvested at various time points and a cell lysate produced. The cell lysate was serially diluted, added to A549 cells and incubated for 5 days and scored for cytopathic effect by the addition of 3-
Cytotoxicity assays A 1 in 10 serial dilution of virus was used to infect a panel of human tumor and non-tumor cells lines in a 96-well plate format. The cells were incubated for 9 days in 2% fetal bovine serum full-growth media and cell viability was assessed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Data were analyzed using the Prizm 4 Software (Graphpad, San Diego, CA, USA).
Transgene expression from E3 and L3 regions of Ad5 M Robinson et al GM-CSF expression assays A549 cells were seeded in a six-well plate and infected with virus at 50 PFU cell À1 in serum-free media. After 90 min, the media was removed and replaced with fresh fullgrowth media720 mg ml À1 cytosine b-D-arabinofuranoside (AraC, Sigma, St Louis, MO, USA) and the supernatant was sampled at various time points. The human GM-CSF level in the supernatants was quantified by enzyme-linked immunosorbant assay (ELISA; R&D Systems, Minneapolis, MN, USA).
In vivo GM-CSF expression assay Female NCR nu/nu (4-6 weeks of age; body weight 18-20 g) were purchased from Simonsen Laboratories (Gilroy, CA, USA). Mice were injected intravenously (i.v.) with 3 Â 10 10 vp in 50 ml. Animals were killed at various time points and the blood harvested. Serum fractions were obtained and the level of hGM-CSF in the serum was quantified by ELISA (R&D Systems). The livers were homogenized and genomic DNA extracted using the Qiagen Tissue DNA Extraction kit (Qiagen, Valencia, CA, USA). The adenovirus genome copies present in the sample was determined using quantitative polymerase chain reaction (qPCR) with a forward (CAACTC CAAGTGCATACTCTATGTC) and a reverse primer (TGTAAGAGGATGTGGCAAATATTTC) specific for fiber, in combination with a fiber-specific probe, 6FAM-TTTCATGGGACTGGTCTGGCCACA-TAMRA.
Results
Construction of GM-CSF insertion site oncolytic adenoviral vectors
The genomic structures of the vectors used in this study are diagrammed schematically in Figure 1a . All vectors are based on the parental vector OV1165, which utilizes the human E2F-1 promoter to control Ad5-E1A, restricting replication of the vector to cells that have a defective or inhibited the pRB pathway. 4, 12 In addition, the SV40 polyadenylation signal (PolyA) was inserted upstream of the E2F-1 promoter to prevent read-through of transcription from the left ITR. 4 The E1 region of the oncolytic vectors contains an intact E1A-and E1B-coding sequence. All the vectors had the hGM-CSF cDNA inserted into either the E3 or L3 region. This transgene was chosen Figure 1 (a) Diagram of GM-CSF insertion vectors. The GM-CSF insertion site vectors were generated from a parental Ad5 vector that has the human E2F-1 promoter in place of the Ad5 E1 promoter. Directly upstream is the SV40 polyadenylation (PolyA) sequence to prevent any upstream effects of the inverted terminal repeat (ITR) promoter on the E2F-1 promoter. The adenoviral packaging sequence (c) is located between the ITR and the SV40 PolyA signal. In the Ad-gp19K-GM vector, the human GM-CSF cDNA replaced the E3 gp19K gene. In the Ad-14.7K-GM vector, the hGM-CSF cDNA replaced the E3 14.7K gene. In the Ad-23K-GM vector, a consensus splice acceptor site (SAS) was engineered directly downstream of the stop codon of the 23K protease gene, with the hGM-CSF cDNA placed immediately downstream of the SAS. In the Ad-Hexon-GM, the hGM-CSF cDNA was placed directly downstream of the 23K SAS and the consensus SAS sequence was placed immediately after the hGM-CSF cDNA. (b) The engineered junction between E3 14.5K and GM-CSF in the Ad-14.7K-GM vector: due to the overlap in coding sequences of the E3 14.5K and E3 14.7K genes in the native Ad5 sequence, the original start codon of E3 14.7K was mutated while keeping the C-terminus of E3 14.5K intact. The hGM-CSF cDNA with a 5 0 Kozak sequence (ACC) was inserted directly downstream of the E3 14.5K stop codon. GM-CSF, granulocyte macrophage colony-stimulating factor; hGM-CSF, human granulocyte macrophage colonystimulating factor.
Transgene expression from E3 and L3 regions of Ad5 M Robinson et al as a marker since it is non-toxic to mice in vivo, is secreted and qualified assays for the quantification of protein levels are available.
The E3 region was chosen as an insertion site in two vectors on the basis of previous studies demonstrating that E3 genes are not essential for viral replication and that transgenes can be successfully inserted into this region, without major impairment of viral function. 18, 20, 22, 32 In the Ad-GM-gp19K vector, the hGM-CSF cDNA was inserted into the E3 gp19K region as previously described for the vector Dgp19B. 22 The hGM-CSF cDNA was inserted in place of the E3 14.7K gene in the second E3-based vector, Ad-GM-14.7. Given the known overlap in coding sequences between the E3 14.7K gene and the upstream E3 14.5K gene in the wild-type adenovirus 33 genome the hGM-CSF cDNA was inserted in the E3 14.7K region in a manner to both optimize GM-CSF expression and maintain the integrity of the E3 14.5K/14.7K overlap sequence. A T to C base mutation was generated in the original ATG start codon of the E3 14.7K gene (Figure 1b ) to enable this insertion. Although the start codon of the E3 14.7K gene is ablated, the C-terminus of E3 14.5-kDa protein is unchanged. The GM-CSF cDNA containing a 5 0 Kozak sequence 34 was then inserted immediately downstream.
The second region that was chosen for transgene insertion was the L3 region of the Ad5 genome. This region was chosen as its mRNA transcripts have been extensively mapped, the L3 mRNA transcript is one of the most abundantly produced in an adenoviral-infected cell and the transcript is produced late in infection. 35 It was therefore predicted that transgenes would be expressed at high levels when inserted into this region. In order to link transgene expression to the genes in the L3 region, a consensus 3 0 splice acceptor site (SAS), which is a sequence that encodes a branch point, polypyrimidine tract and a splice acceptor sequence, was utilized. A sequence similar to the one used here has been shown to allow successful transgene expression that utilizes the adenoviral transcriptional and splicing machinery. 21 In the first L3-based vector, Ad-hexon-GM, the hGM-CSF cDNA was inserted between the hexon gene and the 23K protease gene. A SAS was inserted immediately downstream of the GM-CSF cDNA so that the transcript would be spliced using the splice site within the hexon gene and the 23K transcript would be spliced using the inserted consensus SAS. In the second vector, Ad-23K-GM, the hGM-CSF cDNA with the 5 0 SAS sequence was inserted between the 23K stop codon and the downstream L3 PolyA signal.
Large-scale preparations of all four engineered vectors and the parental vector were made and assayed for PFU and vps. The titers (PFU ml ) and Ad-23K-GM (7.0 Â 10 10 ).
Insertion of transgenes into the E3 and L3 region of the virus had no effect on viral growth or cytotoxicity In order to determine if the transgene insertion site had any impact on the growth of the virus, a single-step growth curve was generated by infecting A549 human lung tumor cells (multiplicity of infection (MOI) ¼ 50 PFU cell À1 in 2% fetal bovine serum Dulbecco's modified Eagle's media. Cell viability was assessed after 9 days using a tetrazolium salt-based assay (MTS reagent). The EC 50 values were determined using Graphpad Prism software. h.p.i., hours post-infection.
Transgene , respectively, which is comparable to that of the parental vector (154 909 PFU ml À1 ). Thus, insertion of GM-CSF cDNA into these vectors had little impact on viral growth. In contrast, the Ad-Hexon-GM vector had a maximum yield of 29 523 PFU ml À1 , approximately one-log lower than the parental vector, indicating that the insertion of the GM-CSF cDNA between the hexon and 23K coding regions had a detrimental effect on viral growth. The insertion of the transgene between the hexon and 23K coding sequences is apparently more disruptive to virus production than when the transgene is inserted downstream of the 23K coding sequence as in Ad-23K-GM vector.
The cytotoxicity of each of the vectors was determined (Figure 2b ) using an EC 50 assay wherein a serial dilution of virus is used to infect cells and the cell viability is determined 9 days post-infection. The EC 50 values were generated using one tumor cell line (A549) and two normal cell lines (Wi38 and MRC5). The EC 50 values of the four insertion site vectors in A549 cells ranged from 0.01 to 0.1 PFU ml
À1
, comparable to the EC 50 value of the parental vector (0.03770.007 PFU ml
). This indicates that the cytotoxicity of the modified viruses is not affected by inserting a transgene into either the E3 or L3 regions. Interestingly, even though the growth of Ad-Hexon-GM was reduced in A549 cells (Figure 2a) (Figure 3 ). The level of GM-CSF expression was compared to a non-replicating E1-deleted Ad5 vector that drives transgene expression from the constitutive cytomegalovirus (CMV) promoter (Ad-GMCSF). The cells were infected in the absence or presence of the DNA replication inhibitor AraC, which is used to demonstrate that transgene expression is dependent on DNA replication of the virus. 18 When cells were infected with the control Ad-GMCSF virus, the amount of GM-CSF in the supernatant increased steadily with time, reaching a maximum of 188 ng ml À1 at 72 h.p.i. As expected, the kinetics of GM-CSF expression from Ad-GMCSF were identical with or without AraC because the expression from the constitutive CMV promoter is not dependent on Figure 3 Determination of the level of transgene expression from the E3 and L3 region insertion sites. A549 cells were infected at an MOI of 50 PFU cell À1 in duplicate, supernatants were collected 10, 24, 36, 48 and 72 h.p.i. and GM-CSF levels were determined by ELISA. The infections were performed in the presence (dotted line) or absence (solid line) of 20 mg ml À1 AraC, a DNA replication inhibitor, to determine if transgene expression occurred in the absence of DNA replication. The level of expression was compared to a non-replicating, E1-deleted Ad-GM-CSF vector that expresses the hGM-CSF cDNA from the constitutive human CMV immediate-early (hCMV-IE) promoter. AraC, cytosine b-D-arabinofuranoside; CMV, cytomegalovirus; ELISA, enzyme-linked immunosorbant assay; GM-CSF, GM-CSF, granulocyte macrophage colony-stimulating factor; hGM-CSF, human granulocyte macrophage colony-stimulating factor; h.p.i., hours post-infection.
Transgene expression from E3 and L3 regions of Ad5 M Robinson et al DNA replication. When GM-CSF was expressed from the transgene inserted in the E3 region in Ad-gp19K-GM and Ad-14.7K-GM, maximum GM-CSF levels 72 h.p.i. were 980 and 2447 ng ml À1 , respectively, in the absence of AraC, which corresponded to approximately fivefold and 13-fold increased expression compared with the control Ad-GMCSF vector (Figure 3 ). In the presence of AraC, however, maximum GM-CSF expression by Ad-gp19K-GM and Ad-14.7K-GM were reduced nine-fold (107 ng ml
) and over 80-fold (28 ng ml À1 ), respectively, compared with expression levels in the absence of AraC. The level of hexon protein, which is only expressed at late times in infection, was also determined by ELISA. In the absence of AraC, high levels of hexon were found at 48-72 h.p.i., but in the presence of AraC, no hexon protein was detected (data not shown), indicating that the presence of AraC had blocked late gene expression. These findings confirm that the majority of the transgene expression from the E3 14.7K locus is via the major late promoter that is dependant on DNA replication. However, although there is a reduction in the level of transgene expression from the E3 14.7K region, the low level of transgene expression still observed in the presence of AraC is possibly due to read through from the early E3 promoter.
GM-CSF levels from Ad-23K-GM and Ad-Hexon-GM were 6018 and 801 ng ml
, respectively, in the absence of AraC, which corresponds to 32-fold and fivefold increases compared with Ad-GMCSF. In fact, the highest levels of GM-CSF were observed with the Ad-23K-GM vector in which the GM-CSF expression from the L3 region is driven exclusively by the major late promoter, 35 indicating its relative strength compared with the E3 and CMV promoters. The reduced level of transgene expression from Ad-Hexon-GM correlates with the reduced viral growth seen with this virus. In the presence of AraC GM-CSF levels were o1 ng ml
À1 at all time points tested with both viral vectors. In summary, insertion of transgenes into the L3 region results in high levels of protein expression that is completely dependent on the successful replication of the viral genome.
Transgene expression is restricted from Ad-14.7-GM and Ad-23K-GM viruses after intravenous administration in nude mice Previous studies have shown that expression of the transgenes can be targeted to the tumor but prevented in non-target organs such as the liver by linking transgene expression to viral replication, 15 thereby improving the safety profile of the vectors. To determine if inserting the transgene into the E3 or L3 regions results in a similarly improved safety profile as observed for the Ad-14.7K-GM or Ad-23K-GM vectors, an in vivo study was performed in which virus was injected into mice i.v. and the level of systemic GM-CSF expression determined (Figure 4 ). With this route of administration, the major target organ for adenovirus uptake is the liver, 36, 37 in which limited replication should occur from an E2F-E1A oncolytic adenovirus. 4, 5 NCR nu/nu mice were injected i.v. with 3 Â 10 10 vps of either Ad-14.7K-GM or Ad-23K-GM, which were the two vectors with the highest level of GM-CSF expression in vitro, or the control Ad-GM-CSF virus. Mice were euthanized 6, 24 and 72 h.p.i. and serum and liver were collected. The serum was analyzed for GM-CSF levels by ELISA and the livers were homogenized to determine the number of adenoviral genome copies by qPCR. The data were plotted as nanograms of GM-CSF expressed per copy of adenoviral genome to standardize for potential differences in virus uptake by the liver. At 24 h.p.i., the number of genome copies in the liver was comparable between all vectors used, at B2000-4000 copies ng À1 of total DNA. High levels of GM-CSF were detected in the serum as early as 24 h after infection with the Ad-GM-CSF control vector, and continued to increase with time, reaching a maximum level at 72 h.p.i. These expression kinetics are expected with the nonreplicating Ad-GMCSF vector, since GM-CSF is expressed from the constitutive human cytomegalovirus (hCMV) promoter and thus dependent only on the number of cells initially transduced. In contrast, up to a five-log reduction in GM-CSF expression at 72 h.p.i. was observed in theAd-14.7K-GM and Ad-23K-GM viruses, even though liver transduction was comparable among all vectors at 6 h.p.i (data not shown). A slight, but not significant, increase in GM-CSF expression was observed with the Ad.14.7K-GM vector compared with the Ad-23K-GM vector. This increase, however, was consistent with the increase in GM-CSF expression seen with Ad-14.7K-GM in vitro, in the presence of AraC when compared with Ad-23K-GM.
Discussion
Arming oncolytic adenoviral vectors with anticancer transgenes may improve the potency of such vectors. Strategies that utilize the adenoviral transcriptional machinery by either replacing adenoviral coding regions of specific genes 15, 18, 22, 32 or linking transgene expression via consensus splice acceptors sites 21 have recently been reported. The latter approach has two main benefits: First, by using the endogenous adenoviral sequences to control transgene expression, as opposed to utilizing exogenous promoters, the overall size of the transgene cassette can be reduced, reducing the constraints on effective packaging of the adenoviral genome. 38 Second, by linking transgene expression to the endogenous adenoviral transcriptional elements, transgene expression will closely mimic that of the adenoviral genes in both temporal expression patterns and, importantly, expression levels. 15, [18] [19] [20] 22, 32 Furthermore, if transgenes are inserted into adenoviral regions that are expressed after DNA replication, transgene expression can be restricted to sites of viral replication, which, in the case of tumor-specific oncolytic viruses, means that expression is restricted to tumors. This provides the opportunity to arm oncolytic viruses with cytotoxic transgenes, but to maintain the vectors' safety profile.
In this study, we characterized several vectors that had various transgene insertion sites, either using a gene replacement strategy or by using a SAS to link transgene expression to adenoviral genes. The human GM-CSF cDNA was chosen as a transgene, as this is a small transgene, which generates a non-toxic secreted protein that can be detected by a simple ELISA method. 22 We determined the effect of the transgene insertion locus within the adenovirus genome on viral growth, cytotoxicity, selectivity and transgene expression both in vitro and in vivo.
In previous studies, the adenovirus E3 region has been used as a site of transgene insertion, as this region had previously been shown not to be essential for viral growth in vitro. 39 In those vectors, either the E3A 20 or E3B 18 region had been deleted and replaced by a transgene. However, these approaches resulted in several genes being deleted simultaneously, which could result in impairment of certain functions of the virus. More recently, vectors have been generated in which only a single gene has been replaced in the E3 region, for example, E3 gp19K.
22
The previously characterized Ad-gp19K-GM vector (OV1193), 28 which utilized this approach, was compared in the current study with a vector that contained the GM-CSF cDNA in place of the E3 14.7K region. Neither insertion resulted in a decrease in viral growth or cytotoxicity in A549 cells compared with the parental vector that contained no transgene. In addition, both of these vectors displayed a level of attenuated replication similar to that of the parental vector in normal cell lines, indicating that the insertion of transgenes into these E3 sites did not affect the selective growth properties of these vectors.
When the maximum level of transgene expression was determined, GM-CSF expression was increased 5-and 13-fold, respectively, in Ad-gp19K-GM and Ad-14.7K, compared with the non-replicating Ad-GM-CSF vector. This increase in transgene expression was dependent on the relative strength of the adenoviral promoters driving GM-CSF expression compared with the CMV promoter, and the level of adenoviral genome replication. In the replication-competent Ad-gp19K-GM and Ad-14.7K-GM vectors, as the level of genome copies increases due to viral replication, a concomitant increase in the level of GM-CSF is observed compared with the non-replicating Ad-GM-CSF control vector. The difference in the expression levels observed between Ad-gp19K-GM and Ad-14.7-GM is likely due to the difference in relative strength of the E3 promoter, which drives expression from the gp19K locus, and the major late promoter, which drives expression from the E3 14.7K locus. This difference in expression levels between the two insertion regions has previously been described. [18] [19] [20] When DNA replication was blocked by AraC no reduction in the level of GM-CSF expression was shown with Ad-GM-CSF, due to the constitutive nature of the CMV promoter. Interestingly, whereas there was only a ninefold reduction of GM-CSF expression observed with the Ad-gp19K-GM vector in the presence of AraC, a greater than 80-fold reduction was seen with the Ad-14.7K-GM vector. This is likely due to the use of the E3 promoter for driving transgene expression from the gp19K locus. The E3 promoter itself is driven by E1A, and its activity is therefore independent of DNA replication. 40 Comparatively, transgene expression in the E3 14.7K locus is driven from the major late promoter, which is only active after DNA replication. 35 Thus, the level of expression of transgenes inserted into the E3 14.7K locus is dependent on the level of viral replication, which results in vectors that demonstrate tumor-specific transgene expression in the case of oncolytic vectors. It is worth mentioning that transgene expression from the E3 region was not completely blocked by AraC. While the E3 14.7K gene is expressed from the major late promoter late during infection, some read-through may occur from the E3 promoter that could result in low level of gene expression even in the absence of DNA replication. In comparison, expression from true late genes, for example hexon, was completely blocked by the presence of AraC (data not shown).
Although this study and others have shown that the use of the E3 region for transgene insertion can result in high level of tumor-specific transgene expression, it does result in deletion of certain genes from the E3 region. Recent studies have shown that deletion of all or parts of the E3 region may have a deleterious effect on in vivo oncolytic activity of the vector, either by reducing the potency of the vector 41 or by increasing the clearance of the vector by the host immune system. 42 Therefore, in this study the L3 region was also evaluated as a novel insertion site and used as consensus SAS to link transgene expression to either the hexon protein or the 23K protease, which resulted in oncolytic vectors with no deletions in the adenoviral genome. A one-log reduction in the growth of Ad-Hexon-GM vector was observed compared with a parental unarmed oncolytic adenovirus, possibly because the insertion of the SAS and transgene affected efficient transcription and translation of the 23K protein that are critical for viral growth. However, when the SAS and transgene were placed downstream of the 23K protease in the Ad-23K-GM vector, no effect was seen on viral growth or cytotoxicity. Interestingly, with Ad-23K-GM, a greater than 30-fold increase in GM-CSF expression was measured compared with the Ad-GM-CSF control vector. This high level of transgene expression was even 3-to 4-fold greater than that of the Ad-14.7K-GM vector, probably because the L3 transcript is one of the most abundant at late time points during adenoviral infection. 35 Importantly, when DNA replication was blocked, no transgene expression was observed from either Ad-23K-GM or Ad-Hexon-GM. Also, in the presence of AraC, no hexon protein could be detected (data not shown), demonstrating that transgene expression from the L3 region mimics the expression kinetics of the L3 genes and is completely dependent on viral replication. The tight regulation of transgene expression from the L3 regions was also observed in vivo. Following injection intravenously, the majority of the virus is taken up by the liver, and serum GM-CSF levels can be used to determine whether transgene expression will occur if a virus infects non-target organs. While high levels of systemic transgene expression was observed with the Ad-GM-CSF constitutive control virus, very low serum levels of GM-CSF were observed with the Ad-23K-GM vector.
In this study, we have compared several adenoviral viruses with different genome insertion sites to determine the effect of transgene insertion locus on various viral characteristics, including growth and oncolytic activity, and the level of transgene expression. Linking transgene expression to the 23K protease region via a consensus SAS resulted in the highest levels of transgene expression observed, and transgene expression was completely dependent on DNA replication both in vitro and in vivo, but did not affect viral growth. In addition, this approach allows arming of the vector, with no deletion of any adenoviral genes. High transgene expression levels were obtained after insertion of the transgene into the E3 14.7K locus. However, low levels of expression occurred even in the absence of DNA replication, which could result in transgene expression in non-target sites.
These data clearly demonstrate the effectiveness of using the adenoviral transcriptional machinery to regulate transgene expression from oncolytic adenoviral vectors. Also, methods of inserting transgenes into regions of the adenoviral genome that are active only late during the infection cycle may allow the generation of viruses that potentially have an improved safety profiles compared with vectors that utilize constitutive promoters or early adenoviral promoters that are not dependent on DNA replication to drive inserted transgenes. While the non-target tissue expression of essentially non-toxic transgene products such as GM-CSF is of less concern, the ability to tightly restrict the expression of cytotoxic transgenes, such as tumor necrosis factor-a, to tumor tissues should result in oncolytic vectors that are both more potent and have an overall improved safety profile.
